Aydin Huseynov
Stock Analyst at Ladenburg Thalmann & Co.
(0.08)
# 4,332
Out of 4,377 analysts
119
Total ratings
34%
Success rate
-18.8%
Average return
Main Sectors:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELTX Elicio Therapeutics | Initiated Coverage: Buy | $20 | $13.18 | +51.75% | 1 | Apr 15, 2026 | |
| IKT Inhibikase Therapeutics | Initiated Coverage: Buy | $4 | $1.63 | +145.40% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiated Coverage: Buy | $40 | $15.07 | +165.43% | 1 | Jan 5, 2026 | |
| URGN UroGen Pharma | Reiterated: Buy | $31 → $55 | $26.85 | +104.84% | 2 | Nov 7, 2025 | |
| IMUX Immunic | Initiated Coverage: Buy | $30 | $12.77 | +134.93% | 1 | Oct 16, 2025 | |
| KALA KALA BIO | Initiated Coverage: Buy | $600 | $2.06 | +29,026.21% | 1 | Jul 11, 2025 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $39 → $48 | $26.71 | n/a | 4 | Mar 20, 2025 | |
| ARDX Ardelyx | Maintained: Buy | $11 | $5.56 | n/a | 1 | Mar 7, 2025 | |
| BDRX Biodexa Pharmaceuticals | Maintained: Buy | $8 → $18 | $3.36 | n/a | 2 | Jan 2, 2025 | |
| CLRB Cellectar Biosciences | Maintained: Buy | $390 | $2.59 | n/a | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 → $24 | $11.12 | n/a | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $7 | $2.04 | n/a | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 → $19 | $1.42 | n/a | 2 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 | $1.43 | n/a | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.12 | n/a | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $1.29 | n/a | 3 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $0.169 | n/a | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $10.13 | n/a | 2 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $6 | $8.23 | n/a | 4 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 → $19 | $0.9431 | n/a | 4 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $50.43 | n/a | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $10 | $1.27 | n/a | 3 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $9.54 | n/a | 2 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $3.40 | n/a | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $10 | $3.90 | n/a | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 → $240 | $1.74 | n/a | 3 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.49 | n/a | 3 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $2.57 | n/a | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0003 | n/a | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.95 | n/a | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.61 | n/a | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $1.89 | n/a | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $635.45 | n/a | 11 | Nov 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $26 → $20 | $57.32 | n/a | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $74.48 | n/a | 5 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $89 | $102.38 | n/a | 5 | Sep 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $3.33 | n/a | 5 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $6.61 | n/a | 2 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $2.52 | n/a | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 → $15 | $1.07 | n/a | 7 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $163.88 | n/a | 1 | Sep 30, 2020 |
Elicio Therapeutics
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $13.18
Upside: +51.75%
Inhibikase Therapeutics
Mar 4, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $1.63
Upside: +145.40%
Akari Therapeutics,
Jan 5, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $15.07
Upside: +165.43%
UroGen Pharma
Nov 7, 2025
Reiterated: Buy
Price Target: $31 → $55
Current: $26.85
Upside: +104.84%
Immunic
Oct 16, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $12.77
Upside: +134.93%
KALA BIO
Jul 11, 2025
Initiated Coverage: Buy
Price Target: $600
Current: $2.06
Upside: +29,026.21%
Capricor Therapeutics
Mar 20, 2025
Reiterated: Buy
Price Target: $39 → $48
Current: $26.71
Upside: n/a
Ardelyx
Mar 7, 2025
Maintained: Buy
Price Target: $11
Current: $5.56
Upside: n/a
Biodexa Pharmaceuticals
Jan 2, 2025
Maintained: Buy
Price Target: $8 → $18
Current: $3.36
Upside: n/a
Cellectar Biosciences
Dec 5, 2024
Maintained: Buy
Price Target: $390
Current: $2.59
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $21 → $24
Current: $11.12
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $5 → $7
Current: $2.04
Upside: n/a
Oct 21, 2024
Maintained: Buy
Price Target: $11 → $19
Current: $1.42
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $16
Current: $1.43
Upside: n/a
Aug 14, 2024
Reiterated: Buy
Price Target: $7
Current: $1.12
Upside: n/a
Jul 30, 2024
Maintained: Buy
Price Target: $6 → $5
Current: $1.29
Upside: n/a
Jun 27, 2024
Initiated Coverage: Buy
Price Target: $10
Current: $0.169
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: n/a
Current: $10.13
Upside: n/a
May 16, 2024
Maintained: Buy
Price Target: $8 → $6
Current: $8.23
Upside: n/a
Apr 18, 2024
Maintained: Buy
Price Target: $9 → $19
Current: $0.9431
Upside: n/a
Mar 14, 2024
Downgraded: Hold
Price Target: n/a
Current: $50.43
Upside: n/a
Nov 10, 2023
Reiterated: Buy
Price Target: $14 → $10
Current: $1.27
Upside: n/a
Nov 9, 2023
Reiterated: Buy
Price Target: $21
Current: $9.54
Upside: n/a
Oct 10, 2023
Initiated Coverage: Buy
Price Target: $10
Current: $3.40
Upside: n/a
Jun 5, 2023
Maintained: Buy
Price Target: $20 → $10
Current: $3.90
Upside: n/a
May 16, 2023
Maintained: Buy
Price Target: $25 → $240
Current: $1.74
Upside: n/a
Mar 10, 2023
Downgraded: Hold
Price Target: n/a
Current: $4.49
Upside: n/a
Dec 7, 2022
Initiated Coverage: Buy
Price Target: $6
Current: $2.57
Upside: n/a
Nov 15, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.0003
Upside: n/a
Nov 4, 2022
Downgraded: Hold
Price Target: n/a
Current: $2.95
Upside: n/a
Aug 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $1.61
Upside: n/a
May 2, 2022
Initiated Coverage: Buy
Price Target: $37
Current: $1.89
Upside: n/a
Nov 9, 2021
Maintained: Hold
Price Target: n/a
Current: $635.45
Upside: n/a
Nov 8, 2021
Upgraded: Buy
Price Target: $26 → $20
Current: $57.32
Upside: n/a
Oct 21, 2021
Maintained: Hold
Price Target: n/a
Current: $74.48
Upside: n/a
Sep 23, 2021
Maintained: Buy
Price Target: $89
Current: $102.38
Upside: n/a
Sep 20, 2021
Maintained: Buy
Price Target: $9
Current: $3.33
Upside: n/a
Aug 6, 2021
Rated: Buy
Price Target: $5
Current: $6.61
Upside: n/a
Jun 21, 2021
Reiterated: Buy
Price Target: $15
Current: $2.52
Upside: n/a
Jan 8, 2021
Maintained: Buy
Price Target: $25 → $15
Current: $1.07
Upside: n/a
Sep 30, 2020
Initiated Coverage: Hold
Price Target: n/a
Current: $163.88
Upside: n/a